Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Insmed Incorporated
Biopharmaceutical company enters exclusive option agreement with UCSF
April 10th, 2005
Insmed Incorporated (INSM) has entered into an exclusive option agreement with University of California, San Francisco School of Medicine (UCSF) for the patented use of IGF-1 receptor antagonists to treat prostate cancer This application of IGF-1 receptor antagonists complements Insmed and UCSF's ongoing clinical studies with INSM-18, a small molecule IGF-1 tyrosine kinase inhibitor in a phase I clinical study in patients with relapsed prostate cancer. Ira D. Goldfine, MD, professor of medicine at UCSF will lead the investigative efforts with IGF-1 receptor antagonists to identify the compound with an ideal risk/benefit ratio to enter clinical...
Source: Aging & Elder Health Week (2005-04-10)
|
